Utilizing itstechnology, DBV is the only company able to propose a non-invasive approach of specific immunotherapy in food allergy.
DBV Technologies mission is to develop innovative products for the diagnosis and treatment of food allergies with an original method capable of influencing the immune response in allergic patients.
The ultimate goal of the DBV project is to safely improve allergen tolerance levels in patients unable to consider treatment for safety reasons due to the severity of their allergies. DBV Technologies is focused on developing targeted allergy therapies specifically for patients with IgE- mediated food allergies with its Epicutaneous Immunotherapy (EPIT) treatment.
Allergen-specific Immunotherapy (SIT) for allergy treatment has been used for the past century and is supported by convincing documentation of its efficacy. Allergen-specific Immunotherapy consists of administering gradually increasing quantities of an allergen product to an individual with IgE-mediated allergic disease in order to improve/reduce/anneal the symptoms associated with subsequent exposure to the causative allergen. It can induce clinical and immunological tolerance which may be maintained years after cessation of the treatment.
DBV Technologies has developed a desensitization method using VIASKIN® technology aimed at developing a cutaneous route for allergen-specific immunotherapy/allergy desensitization, called Epicutaneous ImmunoTherapy (EPIT). This is an effective and completely non-invasive alternative to established subcutaneous allergen-specific immunotherapy (SCIT) or sublingual allergen-specific immunotherapy (SLIT).
DBV’s EPIT method is based on pre-clinical observations and preliminary clinical results obtained in a cohort of children. Its principle involves maintaining an allergen on the skin of an allergic subject for repeated and prolonged periods, in order to achieve clinical desensitization/tolerization. When the allergen-specific VIASKIN® is applied to the skin of a patient with an IgE-mediated allergy, supplied allergens provoke a local reaction, mostly consisting of minor eczematous lesions, which may be considered as a marker of clinical efficacy.
The major differences between epicutaneous and subcutaneous allergen exposure are:
CNIL number: 1544201 v 0
DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83
SIRET: 441772522 00013
Executive editor: Pierre-Henri Benhamou
Hosting service: OVH www.ovh.com
Design : l’enchanteur www.lenchanteur.com